{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-005767","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2024-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.170075+00:00","generated_at":"2026-06-03T07:23:02.645702+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PTC Therapeutics Q1 total revenue $210M, net loss narrows to $91.6M; pipeline milestones on track","bullets":["Q1 total revenue $210M (down ~5% YoY); DMD franchise $161M (Translarna $104M, Emflaza $57M).","GAAP net loss $91.6M, improved from $139M loss in Q1 2023; cash $884.8M.","Submitted MAA for sepiapterin (PKU) and BLA for Upstaza (AADC deficiency) in March 2024.","Plans to resubmit Translarna NDA mid-2024; PIVOT-HD (PTC518) interim data in Q2 2024.","Reaffirmed FY2024 total revenue guidance $600-680M; GAAP R&D/SG&A $740-835M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-005767","json":"https://secwatch.observer/filing/0001558370-24-005767.json","markdown":"https://secwatch.observer/filing/0001558370-24-005767.md","text":"https://secwatch.observer/filing/0001558370-24-005767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/0001558370-24-005767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/tmb-20240425x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T07:23:02.645702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"15e77244f47e4276ddbfaae79fe23c4870502820","claim":"PTC THERAPEUTICS, INC. reported the first quarter ending March 31, 2024 results: revenue $210.1 million, net income $91.6 million. Guidance reaffirmed.","evidence_excerpt":"many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin.\" ​ Key Corporate Updates: ● First quarter 2024 total revenue of $210 million ● First quarter 2024 revenue for the DMD franchise was $161 million o TranslarnaTM (ataluren) net product revenue was $104 million, driven by new patients in existing geographies","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070081/000155837024005767/0001558370-24-005767-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ending March 31, 2024"},{"label":"Revenue","value":"$210.1 million"},{"label":"Net income","value":"$91.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}